Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753311 | 0.82 | NPC1 (0.47) | TACR1KMT2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7012505 | 0.80 | TACR1 (0.43) | TACR1KMT2ASMN1; SMN2MEN1KDM4E | |
| SCHEMBL7211766 | 0.78 | KMT2A (0.39) | TACR1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL7099931 | 0.76 | CRBN (0.40) | TACR1KMT2AALDH1A1 | |
| SCHEMBL23610494 | 0.71 | KMT2A (0.49) | TACR1KMT2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7211759 | 0.71 | NPC1 (0.39) | TACR1KMT2ALMNAMEN1AKR1B1 | |
| SCHEMBL7211763 | 0.71 | TACR1 (0.37) | TACR1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL4146171 | 0.68 | USP30 (0.39) | SMN1; SMN2KDM4E | |
| SCHEMBL21150760 | 0.67 | TACR1 (0.43) | TACR1SMN1; SMN2KDM4E | |
| SCHEMBL21753397 | 0.66 | NPC1 (0.43) | TACR1KMT2ALMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | TACR1 1484/4885KMT2A 636/4885POLB 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.